Journal
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Volume 40, Issue 7, Pages 279-286Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.urolonc.2020.01.019
Keywords
Bladder cancer; Mutation; Mutation signature; APOBEC; Genomics
Categories
Funding
- Jesse Brown VA Medical Center, Chicago, IL [BX003692]
- John P. Hanson Foundation for Cancer Research (Milwaukee, WI)
Ask authors/readers for more resources
This review discusses the full spectrum of the genomic landscape of muscle-invasive bladder cancer (MIBC) toward the goal of therapeutic application.
The Cancer Genome Atlas (TCGA) for bladder cancer was published in 2014 with updated annotation of over 400 patients with muscle-invasive bladder cancer (MIBC) in 2017. This tremendous work established the foundation of the genomic landscape of MIBC. The next steps to utilize information from The Cancer Genome Atlas is to (1) identify the causes of mutation, (2) determine the significant differences and sources of heterogeneity, and (3) apply these tools toward patient care. In this review, we discuss the full spectrum of the genomic landscape of MIBC toward the goal of therapeutic application. (C) 2020 Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
